Pyxis Oncology Inc (PYXS)

$4.36 -0.12 (-2.68%)
Market Cap 278.94M
Revenue (ttm) 16.15M
Net Income (ttm) -77.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -478.82%
Debt to Equity Ratio 0.00
Volume 665,400
Avg Vol 837,858
Day's Range N/A - N/A
Shares Out 62.26M
Stochastic %K 63%
Beta 1.41
Analysts Strong Sell
Price Target $6.91

Company Profile

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 cl...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 453 3596
Address:
321 Harrison Avenue, 11th Floor, Suite 1, Boston, United States
RadioIsotope25
RadioIsotope25 Nov. 12 at 11:22 PM
Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204 $ADCT $PYXS https://finance.yahoo.com/news/radiopharm-theranostics-starts-enrollment-third-133000810.html
0 · Reply
Hawaiiansurf1
Hawaiiansurf1 Nov. 12 at 9:51 PM
$PYXS Listen to the Nov 11th & 12th Investor Conferences on the PYXS website. My Take Away: 1. Best in Class MOA 2. Best initial End of Life Results (1 CR, 2 PR, 100% progression free). Artificial Intelligence Models predict superior Best in Class results. Combo and Mono Results /Business Plans will be made public by December 31, 2025. Combo results of 65% plus will guarantee First Line. Mono results of 35% will guarantee second and third line. All indications predict better results than leading competition "Merus." Merus sold recently for 7+ Billion ($97 Share). Hold on to your shares!
0 · Reply
RadioIsotope25
RadioIsotope25 Nov. 12 at 3:25 AM
$PYXS $30
0 · Reply
DavidMacph1
DavidMacph1 Nov. 11 at 1:23 PM
$PYXS VPA supported cup and handle. Solid uptrend with continuation. Breakout today on good relative volume Entry seems safe here with only one major local resistance near $7. The projected price based on the pattern is near 13. Old resistance above that near $14. Join Xtrades with the link in bio.
0 · Reply
EverestTrader
EverestTrader Nov. 11 at 1:09 PM
$PYXS
0 · Reply
Emily_Porter_13
Emily_Porter_13 Nov. 11 at 11:41 AM
$PYXS VPA supported cup and handle. Solid uptrend with continuation. Breakout today on good relative volume Entry seems safe here with only one major local resistance near 7$ Projected price based on pattern is near 13. Old resistance above that near 14$
0 · Reply
HoHoHoHum
HoHoHoHum Nov. 11 at 11:31 AM
$PYXS love the action here. Hopefully big prize soon.
0 · Reply
jerry81
jerry81 Nov. 10 at 8:49 PM
$PYXS Ok what’s the joke (: Loving it. After hour PR ?
0 · Reply
Momo7002momo
Momo7002momo Nov. 10 at 5:51 PM
$PYXS and $SCYX hit screener watch out
0 · Reply
Bullbear1010101
Bullbear1010101 Nov. 10 at 5:44 PM
$PYXS what
0 · Reply
Latest News on PYXS
Pyxis Oncology to Participate in Upcoming Investor Conferences

Nov 3, 2025, 4:05 PM EST - 11 days ago

Pyxis Oncology to Participate in Upcoming Investor Conferences

Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 7:00 AM EST - 12 days ago

Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results

Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings

Oct 13, 2025, 4:05 PM EDT - 4 weeks ago

Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

Oct 9, 2025, 7:30 AM EDT - 5 weeks ago

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 30, 2025, 4:24 PM EDT - 6 weeks ago

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pyxis Oncology to Participate in September Investor and Industry Conferences

Aug 21, 2025, 7:30 AM EDT - 3 months ago

Pyxis Oncology to Participate in September Investor and Industry Conferences

Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 4:05 PM EDT - 3 months ago

Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 7:00 AM EDT - 6 months ago

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

May 14, 2025, 7:30 AM EDT - 6 months ago

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Apr 25, 2025, 1:17 PM EDT - 7 months ago

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Apr 2, 2025, 7:30 AM EDT - 8 months ago

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 8 months ago

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 18, 2025, 7:30 AM EDT - 8 months ago

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

Mar 3, 2025, 7:30 AM EST - 9 months ago

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Feb 26, 2025, 7:30 AM EST - 9 months ago

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

Feb 4, 2025, 7:30 AM EST - 10 months ago

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

Dec 19, 2024, 4:08 PM EST - 11 months ago

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead

Dec 7, 2024, 1:30 AM EST - 1 year ago

Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns

Nov 21, 2024, 9:18 AM EST - 1 year ago

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

Nov 20, 2024, 4:05 PM EST - 1 year ago

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside

Nov 8, 2024, 1:30 PM EST - 1 year ago

Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside

Moment Of Truth Approaches For Pyxis Oncology

Sep 13, 2024, 7:08 AM EDT - 1 year ago

Moment Of Truth Approaches For Pyxis Oncology

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference

Jul 29, 2024, 8:00 AM EDT - 1 year ago

Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

Jun 10, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

May 30, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

May 14, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference

May 9, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Mar 27, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

Mar 21, 2024, 7:30 AM EDT - 1 year ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

Mar 13, 2024, 8:00 AM EDT - 1 year ago

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

Mar 7, 2024, 4:30 PM EST - 1 year ago

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting

Mar 5, 2024, 4:45 PM EST - 1 year ago

Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

Nov 7, 2023, 4:30 PM EST - 2 years ago

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023

Sep 27, 2023, 9:18 AM EDT - 2 years ago

Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023

Pyxis Oncology: Catalysts Ahead, Cash In Hand And An Acquisition Completed

Sep 7, 2023, 8:09 AM EDT - 2 years ago

Pyxis Oncology: Catalysts Ahead, Cash In Hand And An Acquisition Completed

Pyxis Oncology to Participate in Two Upcoming Investment Conferences

Aug 31, 2023, 4:01 PM EDT - 2 years ago

Pyxis Oncology to Participate in Two Upcoming Investment Conferences

Pyxis Oncology Successfully Completes Acquisition of Apexigen

Aug 23, 2023, 8:35 AM EDT - 2 years ago

Pyxis Oncology Successfully Completes Acquisition of Apexigen

Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update

Aug 11, 2023, 7:00 AM EDT - 2 years ago

Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update

APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

Aug 10, 2023, 2:56 PM EDT - 2 years ago

APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference

Aug 1, 2023, 4:01 PM EDT - 2 years ago

Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference

CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan

Jul 10, 2023, 3:01 AM EDT - 2 years ago

CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan

Pyxis: Unique ADC Approach With A Catalyst In Late 2023

Jun 15, 2023, 8:20 AM EDT - 2 years ago

Pyxis: Unique ADC Approach With A Catalyst In Late 2023

Pyxis Oncology: A High-Stakes Gambit In The Battle Against Solid Tumors

Jun 12, 2023, 2:59 AM EDT - 2 years ago

Pyxis Oncology: A High-Stakes Gambit In The Battle Against Solid Tumors

APEXIGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

May 30, 2023, 10:52 PM EDT - 2 years ago

APEXIGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs

May 30, 2023, 8:30 AM EDT - 2 years ago

Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs

Pyxis Oncology to Acquire Apexigen

May 24, 2023, 6:45 AM EDT - 2 years ago

Pyxis Oncology to Acquire Apexigen

Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update

May 11, 2023, 7:00 AM EDT - 2 years ago

Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update

RadioIsotope25
RadioIsotope25 Nov. 12 at 11:22 PM
Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204 $ADCT $PYXS https://finance.yahoo.com/news/radiopharm-theranostics-starts-enrollment-third-133000810.html
0 · Reply
Hawaiiansurf1
Hawaiiansurf1 Nov. 12 at 9:51 PM
$PYXS Listen to the Nov 11th & 12th Investor Conferences on the PYXS website. My Take Away: 1. Best in Class MOA 2. Best initial End of Life Results (1 CR, 2 PR, 100% progression free). Artificial Intelligence Models predict superior Best in Class results. Combo and Mono Results /Business Plans will be made public by December 31, 2025. Combo results of 65% plus will guarantee First Line. Mono results of 35% will guarantee second and third line. All indications predict better results than leading competition "Merus." Merus sold recently for 7+ Billion ($97 Share). Hold on to your shares!
0 · Reply
RadioIsotope25
RadioIsotope25 Nov. 12 at 3:25 AM
$PYXS $30
0 · Reply
DavidMacph1
DavidMacph1 Nov. 11 at 1:23 PM
$PYXS VPA supported cup and handle. Solid uptrend with continuation. Breakout today on good relative volume Entry seems safe here with only one major local resistance near $7. The projected price based on the pattern is near 13. Old resistance above that near $14. Join Xtrades with the link in bio.
0 · Reply
EverestTrader
EverestTrader Nov. 11 at 1:09 PM
$PYXS
0 · Reply
Emily_Porter_13
Emily_Porter_13 Nov. 11 at 11:41 AM
$PYXS VPA supported cup and handle. Solid uptrend with continuation. Breakout today on good relative volume Entry seems safe here with only one major local resistance near 7$ Projected price based on pattern is near 13. Old resistance above that near 14$
0 · Reply
HoHoHoHum
HoHoHoHum Nov. 11 at 11:31 AM
$PYXS love the action here. Hopefully big prize soon.
0 · Reply
jerry81
jerry81 Nov. 10 at 8:49 PM
$PYXS Ok what’s the joke (: Loving it. After hour PR ?
0 · Reply
Momo7002momo
Momo7002momo Nov. 10 at 5:51 PM
$PYXS and $SCYX hit screener watch out
0 · Reply
Bullbear1010101
Bullbear1010101 Nov. 10 at 5:44 PM
$PYXS what
0 · Reply
Jusprag24
Jusprag24 Nov. 10 at 4:07 PM
$PYXS This is it I've been trapped in this thing for years let's get it finally running for good
0 · Reply
UltimateTrader_22
UltimateTrader_22 Nov. 7 at 2:21 PM
$CRDL Zacks Equity Research discusses Akebia Therapeutics $AKBA, Ironwood Pharmaceuticals $IRWD, Pyxis Oncology $PYXS, Cardiol Therapeutics $CRDL and Plus Therapeutics $PSTV. Industry: Pharma Link: https://zacks.com/commentary/2767977/5-small-drug-stocks-to-buy-as-the-industry-shows-some-recovery@MoonMarket_ @ZacksResearch @CardiolRx
2 · Reply
Hawaiiansurf1
Hawaiiansurf1 Nov. 6 at 9:20 PM
$PYXS Huge Upside, Best in Class MOA, HNSCC N=6 (1 CR, 2 PR, 3 Progression Free) before combo with MRK, Perfect Value indicator "Merus" bought out for $97 share. We are Golden - Hold your shares for the ride of your life!
1 · Reply
Bullbear1010101
Bullbear1010101 Nov. 4 at 11:04 PM
$PYXS ouch sold 2.4 area
1 · Reply
anachartanalyst
anachartanalyst Nov. 4 at 4:02 PM
$PYXS https://anachart.com/wp-content/uploads/ana_temp/1762272115_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Nov. 4 at 3:37 PM
Guggenheim updates rating for Pyxis Oncology ( $PYXS ) to Buy, target set at 5 → 7.
0 · Reply
RadioIsotope25
RadioIsotope25 Nov. 4 at 3:05 PM
$RADX If Radioharm Theranostics has good her2 data for rad202 end of year at 75mci this will imo can quadruple. I am hopeful we see data end of year they stated publicly they started dosing 75mci in October. $8-9 billion dollar market. Could see it surging like $PYXS considering the market cap do $RADX is only around $60 million.. company already publicly stated they are seeing greater than anticipated tumor uptake at 30mci. I think it spells well for higher doses and warhead (Lu-177) is the same as Lutathera and Pluvicto the blockbusters in this space. $LNTH and Lantheus just bumped their ownership up to 14.5%…
0 · Reply
Quantumup
Quantumup Nov. 4 at 12:33 PM
Guggenheim⬆️ $PYXS's PT to $7 from $5, reiterated at a Buy, and said, PYXS' planned 4Q25 MICVO phase 1 data update is now going to be more robust and answer important investor questions about its competitive positioning in HNSCC. $MRK $CRBP Guggenheim went on to say:
0 · Reply
look2theblue
look2theblue Nov. 3 at 11:18 PM
$ITRM When you least expect it, this will climb just like $PYXS did. Another one of my favorite holdings.
2 · Reply
Stockprofiler
Stockprofiler Nov. 3 at 8:42 PM
$CRDL Cardiol Therapeutics For Immediate Release Chicago, IL – Zacks Equity Research discusses Akebia Therapeutics $AKBA, Ironwood Pharmaceuticals $IRWD, Pyxis Oncology $PYXS, Cardiol Therapeutics $CRDL and Plus Therapeutics $PSTV. Industry: Drugs (non-Big Pharma) Link: https://zacks.com/commentary/2767977/5-small-drug-stocks-to-buy-as-the-industry-shows-some-recovery $CRDL Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics October 2025 @ZacksResearch
0 · Reply
RunnerSignals
RunnerSignals Nov. 3 at 5:53 PM
wild rides ahead 🎢 $FGL $PYXS $LUMN $MBRX $GETY went full rollercoaster today huge intraday swings and wild momentum
0 · Reply
DARKP00L
DARKP00L Nov. 3 at 5:02 PM
$PYXS 11:50 on Nov. 03 2025 Pyxis Oncology shares are trading higher. The company reported Q3 financial results. #tradeideas
0 · Reply